首页> 美国卫生研究院文献>Annals of Oncology >P-147Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment

【2h】

P-147Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment

机译：P-147最终分析：伊立替康/ S-1 /西妥昔单抗（IRIS / Cet）作为KRAS外显子2野生型mCRC患者的二线治疗的II期试验：HGCSG0902。西妥昔单抗治疗的给药间隔比较

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Annals of Oncology
作者
S. Yuki; Y. Komatsu; H. Nakatsumi; Y. Kawamoto; T. Muranaka; K. Sawada; Y. Tsuji; A. Hosokawa; M. Nakamura; O. Muto; T. Sasaki; I. Iwanaga; K. Hatanaka; A. Sato; K. Eto; K. Furukawa; M. Tateyama; Y. Takahashi; S. Sogabe; T. Honda; N. Sakamoto; Y. Sakata;
展开▼
作者单位

展开▼
年(卷),期 -1(27),Suppl 2
年度 -1
页码 ii43
总页数 1
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. CMAB009联合伊立替康或伊立替康单药二线治疗氟嘧啶和奥沙利铂治疗失败的KRAS野生型转移性结直肠癌患者的研究:一项前瞻性、开放、随机、Ⅲ期试验 [J] . 石远凯, 白丽, 张沂平, 癌症（英文版） . 2020,第007期
2. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial [J] . ELez E., Kocakova I., Hoehler T., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第1期

机译：阿比妥珠单抗联合西妥昔单抗联合伊立替康与单独西妥昔单抗联合伊立替康治疗KRAS野生型转移性结直肠癌患者：I / II期POSEIDON随机试验
3. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study) [J] . Takahashi Takao, Emi Yasunori, Oki Eiji, Cancer chemotherapy and pharmacology. . 2016,第3期

机译：在先前接受伊立替康，奥沙利铂和氟嘧啶治疗的KRAS外显子2野生型不可切除结直肠癌患者中，西妥昔单抗和S-1联合治疗的多中心II期研究（KSCC 0901研究）
4. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10 [J] . Kienle Dirk L., Dietrich Daniel, Ribi Karin, Journal of geriatric oncology . 2019,第2期

机译：西妥昔单抗单药治疗和西妥昔单抗加上股票素作为老年患者的一线治疗，患者和BRAF野生型转移性结肠直肠癌。多中心第二期试验SAKK 41/10的结果
5. CONVECTION ENHANCED DELIVERY OF CETUXIMAB FOR THE TREATMENT OF CANINE INTRACRANIAL GLIOMAS: THE UGA BRAIN TUMOR TRIAL [C] . SR Piatt, M. Kent, AC Freeman, American College of Veterinary Internal Medicine Forum . 2012

机译：对流增强甲磺昔单抗的递送治疗犬颅内神经瘤：UGA脑肿瘤试验
6. P-052Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer [O] . H. Osumi, E. Shinozaki, M. Suenaga, -1

机译：P-052两周一次的西妥昔单抗和伊立替康作为II线治疗在KRAS exon2野生型转移性结直肠癌预治疗患者中的三线治疗研究
7. PCN171 Cost-Effectiveness Analysis Of Panitumumab + Folfox Compared To Cetuximab + Folfiri As First-Line Treatment For Patients With Wild-Type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) Metastatic Colorectal Cancer (Mcrc) In Colombia [O] . Vargas-Valencia J, Garcia Perlaza J 2015

机译：帕尼单抗+ Folfox与西妥昔单抗+ Folfiri相比一线治疗PCN171成本效益分析

P-147Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment

著录项

相似文献

相关主题

期刊订阅